Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of September 2026. The report discloses a specific executive compensation event rather than general corporate financial performance. GSK plc is a global biopharma company headquartered in London, England.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data presented relates to a specific equity award transaction:
- Instrument: Ordinary Shares of 31 1/4 pence each (ISIN: GB00BN7SWP63).
- Transaction Type: Conditional award under the 2017 Performance Share Plan.
- Volume: 85,714 shares.
- Price: £18.3750 per share.
- Recipient: Roanne Parry, Chief People Officer and Executive Committee member.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document serves as a regulatory notification of a new equity grant to a Person Discharging Managerial Responsibilities (PDMR) following her appointment on May 1, 2026.
Guidance, Outlook, and Risks
Performance Conditions: The award is subject to a three-year performance period from January 1, 2026, to December 31, 2028. Vesting is contingent upon achieving performance measures set by the Remuneration Committee, which align with those granted to other Executive Committee members in February 2026.
Dividend Rights: Dividends will accrue on the conditional award during the performance period but will only vest if the underlying award vests at the end of the period.
Risks: If performance targets are not met, the unvested portion of the award will lapse.
Investor Verification Checklist
- Verify the specific performance metrics defined in the February 16, 2026, announcement referenced in the filing.
- Confirm the total number of shares outstanding and the dilution impact of this specific award.
- Review the Remuneration Committee's annual report for details on the vesting schedule and clawback provisions.
- Note that this filing contains no data on GSK's 2026 financial results; refer to Form 20-F or quarterly earnings releases for that information.